• Lien Malvoyant
  • Lien Contrasté
  • Lien Contrasté
  • Lien Contrasté Avancé
  • Lien Zoom plus
  • Lien Zoom moins
  • Lien Langue anglaise French Deutsch
  • Home
  • Company
  • Technology
  • Patients
  • Clinical trial
  • Media
  • Investors
  • Professionals
  • Contact us
  • Letter from the Chairman
  • Share Information
  • Press Releases
  • Conferences
  • Financial Reports and Documents
  • Broker research
  • Other Regulated Information
  • Analyst Coverage
  • Shareholder's General Meeting
  • Financial Calendar
  • Contact

Broker research







Twitter @PixiumVision

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.
  • Company

    • About Pixium Vision
    • Management
    • Board of Directors
    • Scientific & Medical Advisors
    • Partners
  • Technology

    • Technology
    • Bionic Vision System Technology
    • Smart Bioinspired Neuromorphic (Event-Based) Camera
    • IRIS® Bionic Vision System
    • PRIMA Bionic Vision System
  • Patients

    • Overview
    • Blindness
    • Retinitis Pigmentosa (RP)
    • Age-related macular degeneration (AMD)
    • Useful Links
  • Clinical trial

    • Overview
    • Dry AMD PRIMA
    • Retinitis pigmentosa IRIS® II
    • Contact
  • Media

    • Press Releases
    • In the News
    • Events
    • Publications
    • Press Kit
  • Investors

    • Letter from the Chairman
    • Share Information
    • Press Releases
    • Conferences
    • Financial Reports and Documents
    • Broker research
    • Other Regulated Information
    • Analyst Coverage
    • Shareholder's General Meeting
    • Financial Calendar
    • Contact
  • Professionals

    • Technology
    • Indications
    • Clinical trial
  • Contact us

    • Contact us
    • Job opportunities
© Copyright PIXIUM VISION. ALL RIGHTS RESERVED. | LEGAL INFORMATION | DESIGN : AGENCE K2  

Recevoir la newsletter
de Frédéric Vardon

Pour vous tenir informé de l’actualité du chef ainsi que de ses évènements et offres exceptionnelles, merci de compléter le formulaire ci-dessous :